literature

HIV mutation literature information.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

PMID: 29566538 2018 Antiviral chemistry & chemotherapy

Method: In total, 94 of 100 samples from patients failing ARV treatment also carried HIV-1 NRTI resistane mutations including M184V (82%), K65R (35%), L74I (19%), M41L (17%) or D67N (17%).

Short Communication: Discordance in Drug Resistance Mutations Between Blood Plasma and Semen or Rectal Secretions Among Newly Diagnosed HIV-1-Infected Thai Men Who Have Sex with Men.

PMID: 29756454 2018 AIDS research and human retroviruses

Abstract: Three participants had DRAMs in anogenital compartments that were not detected in blood plasma-one had DRAMs in semen that was not detected in blood plasma (I54FI) and two had DRAMs in rectal secretions that was not detected in blood plasma (I47IM; K70N, L74I, Y115F, M184V, K103N, V108I, and H221Y).

HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.

PMID: 29844604 2018 Scientific reports

Discussion: The codon L74I is selected for by ABC.

Discussion: This patient has the following resistance codons: M41L, D67H, T69N, K70R, L74I, V118I, T215F, K219E, K219Q and K103Y.

The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.

PMID: 30174310 2018 Cell chemical biology

Introduction: Moreover, we found that nine amino acid substitutions, namely, M41L, D67Delta, T69G, K70R, L74I, V75T, M184V, T215F, and K219Q (in HIV-1EFdAR), were associated with EFdA resistance.

Method: Recombinant HIV-1 clones (HIV-1K65R, HIV-1A114V, HIV-1Y115A, HIV-1F160A, HIV-1M184V HIV-1D185A HIV-1T215F HIV-1D67del/T69G/K70R/L74I/V75T [HIV-167-75], and HIV-1D67del/T69G/K70R/L74I/V757T/M184V/

PMID: 30409215 2018 AIDS research and therapy

Result: As expected, the number and type of mutations with frequencies > 20% (those within Sanger sequencing-based detection level) matched the cART history of the patient, e.g., the virus from patient SG28 had mutations associated with resistance to ABC (L74I 97.6% frequency), 3TC (M184V 99.7%), and EFV (K103N 98.8%, P225H 99.5%) and had been exposed to RTV, DRV, ABC, 3TC, and EFV; while patient SG86 had a virus with resistance to FTC (M184V 98.9%) and RAL (L74M 97.9%, E92Q 86.1% and T97A 99.8%) after being treated over the years with RTV, LPV, DRV, FTC, TDF, and RAL (Additional file 1: Table S1).

Result: Most of the minority mutations in viruses from both groups of naive patients were observed in the

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

PMID: 30119633 2018 Retrovirology

Result: Selection of strain E78004 with CAB resulted in high level resistance along a Q148R/E138K/G140GS/L74I pathway (Table 4).

Result: Similarly, 96USSN20 and E78004 viruses developed resistance along a Q148R pathway leading to L74M/E138K/G148R/R263K and L74I/E138K/G140S/Q148R conferring cross-resistance to all INSTIs.

Result: The outgrowth of the L74I/E138K/G140GS,

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

PMID: 28891788 2017 HIV clinical trials

Method: Primary NRTI-R substitutions assessed were M41L, A62V, K65R, D67N, T69 insertions, K70E/R, L74I/V, V75I, F77L, Y115F, F116Y, Q151M, M184V/I, L210W, T215F/Y, and K219E/N/Q/R in RT.

Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.

PMID: 29049402 2017 PloS one

Table: L74I

Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.

PMID: 29137637 2017 Virology journal

Method: 26, September 2016), HIV-GRADE (http://www.hiv-grade.de, version January 16, 2017), and Rega (https://rega.kuleuven.be/cev/avd/software/rega-algorithm, v9.0.1, October 29, 2013) were considered: A49G, H51Y, V54I, L68IV, L74I, E92V, Q95K, H114Y, G118R, S119R, T124A, A128T, E138T, G140C, Y143AGS, P145S, Q146IKLPR,

Table: L74I

Resistance-Associated Mutations and Polymorphisms among Integrase Inhibitor-Naive HIV-1 Patients in Kuwait.

PMID: 29212076 2017 Intervirology

Abstract: However, the accessory mutation E157Q was found in 1 patient with CRF02_AG, and the polymorphic mutations L74M/I that may contribute to a reduced susceptibility to INSTIs in the presence of major mutations were observed in 6 (13.3%) patients with non-B subtypes and 1 (12.5%) patient with the B subtype.

Browser Board

Co-occurred Entities

Filtrator